The Global Ripple Effect: How Montana’s Right-to-Try Law Could Bridge the Cure Gap in Northeast India
Introduction: A Father’s Fight and a Healthcare Paradox
The first time Kris DeVault heard his son Brody’s cries, he knew something was wrong. Brody, then just a few months old, was exhibiting symptoms of severe developmental delays, muscle weakness, and a relentless inability to thrive. The diagnosis arrived: creatine transporter deficiency (CTD), a rare genetic disorder affecting the brain and nervous system. While CTD has no established cure, emerging biotechnological breakthroughs—particularly gene therapies and enzyme replacements—hold the potential to transform lives. Yet, for families like DeVault’s, the reality remains stark: regulatory delays, financial barriers, and systemic failures often leave them with no choice but to navigate a broken healthcare system alone.
Montana’s recent legislative innovation, the Right-to-Try Law, has emerged as a radical solution to this crisis. Enacted in 2021, the law allows patients and their families to access experimental treatments outside traditional clinical trials, bypassing bureaucratic red tape that can take years to clear. The law’s impact has been profound—not just in Montana, but in sparking global conversations about accessible medical innovation, ethical healthcare distribution, and the human cost of regulatory bottlenecks.
Yet, the story of Brody’s struggle extends far beyond Montana’s borders. In Northeast India, where rare diseases disproportionately affect marginalized communities, the healthcare system remains woefully underprepared. While India hosts one of the world’s largest biotech industries, its ability to deliver cutting-edge treatments to those who need them most remains constrained by underfunded research, lack of infrastructure, and cultural barriers. The question arises: Could Montana’s Right-to-Try model serve as a blueprint for India’s rare disease patients?
This article explores how Montana’s legislative innovation—rooted in a human-centered approach to medical access—could be adapted to address the global gap between scientific promise and practical reality. By examining Brody’s case, the regulatory challenges in Northeast India, and the broader implications of decentralized medical innovation, we uncover a critical opportunity to rethink how healthcare systems prioritize life-saving treatments for the most vulnerable.
The Science of CTD: A Rare Disorder with Devastating Consequences
Creatine transporter deficiency (CTD) is a neurodegenerative disorder caused by mutations in the CRAM1 gene, which disrupts the brain’s ability to produce creatine—a critical energy molecule essential for neural function. Without adequate creatine, children like Brody experience:
- Severe developmental delays (often diagnosed as autism or cerebral palsy)
- Muscle atrophy and hypotonia (weakness and poor motor control)
- Neurological deterioration, including seizures and cognitive decline
The condition is inherited in an autosomal recessive manner, meaning two copies of the defective gene are required for manifestation. While CTD affects fewer than 50,000 people worldwide, its impact is disproportionately severe in low-resource settings, where early diagnosis and intervention are rare.
The Global Rare Disease Crisis: Why CTD Matters
Rare diseases—defined as affecting fewer than 200,000 individuals in the U.S.—comprise over 350 distinct conditions, yet they account for only 1-2% of the global disease burden. Despite their infrequency, they represent a massive unmet medical need:
- Only 500 of the 5,000+ rare diseases have been validated for treatment.
- The average time from discovery to FDA approval is 12-14 years, with many therapies failing due to lack of patient enrollment in clinical trials.
- Families spend an average of $30,000 per year on experimental treatments, often with no guarantee of efficacy.
Brody’s case is not unique. In Northeast India, where neurological disorders are underdiagnosed and undertreated, CTD and other rare diseases remain a hidden epidemic. Studies suggest that neurological conditions account for 30-40% of pediatric hospital admissions, yet only a fraction receive specialized care.
The Role of Biotech in CTD Treatment: Gene Therapy and Beyond
While CTD currently lacks a cure, gene therapy and enzyme replacement therapies are emerging as potential solutions. Companies like CRAM Therapeutics and BioMarin Pharmaceuticals are developing CRAM1 gene therapy, which aims to restore normal creatine transport. Early clinical trials have shown promising results in animal models, but regulatory hurdles and high costs remain major obstacles.
In Montana, the Right-to-Try Law has already enabled families to access pre-approved experimental treatments outside traditional clinical trial pathways. For Brody’s family, this means:
- Faster access to emerging therapies before formal FDA approval.
- Reduced financial burden, as experimental treatments are often not covered by insurance.
- A pathway to participate in clinical trials, even if they are not yet widely available.
Yet, the question remains: Can this model be replicated in India’s complex healthcare ecosystem?
Montana’s Right-to-Try Law: A Model for Global Healthcare Reform?
Montana’s Right-to-Try Law was inspired by Brody’s story and the broader struggle of families seeking access to experimental treatments. The law, passed in 2021, allows patients and their families to:
- Request access to investigational drugs from pharmaceutical companies.
- Receive treatments outside clinical trials, provided the drug is deemed safe in prior studies.
- Participate in clinical trials if approved by the FDA.
Key Features of the Law and Its Impact
| Aspect | Montana’s Approach | Global Implications |
|--------------------------|-----------------------|------------------------|
| Regulatory Flexibility | Bypasses FDA approval for urgent cases | Could accelerate access in low-resource settings where trials are slow |
| Financial Barriers | Companies may waive costs for qualifying patients | Could reduce out-of-pocket expenses for rare disease families |
| Ethical Considerations | Ensures informed consent and medical oversight | Must balance patient rights with scientific integrity |
Since its enactment, Montana has seen over 500 Right-to-Try requests, with many families gaining access to life-saving treatments that would otherwise be unavailable. The law has also sparked debates about:
- The ethics of expedited access without full clinical trial data.
- The role of pharmaceutical companies in funding such programs.
- The potential for abuse in cases where treatments are not proven effective.
Could Montana’s Model Work in Northeast India?
India’s healthcare system presents unique challenges that must be addressed if the Right-to-Try concept is to succeed:
- Regulatory Complexity: India’s Drug Controller General of India (DCGI) has a strict approval process, often delaying access to experimental treatments.
- Infrastructure Gaps: While India has emerging biotech hubs (like Bengaluru and Hyderabad), rural and tribal areas lack specialized care.
- Financial Accessibility: Out-of-pocket expenses for rare disease treatments can be prohibitive, even in middle-income countries.
A Case Study: The Northeast Indian Rare Disease Landscape
Northeast India, often called the "India’s Last Frontier," is home to diverse ethnic groups with unique genetic susceptibilities. Studies suggest that:
- Neurological disorders account for 25% of pediatric hospitalizations in the region.
- Only 10-15% of rare diseases are diagnosed due to lack of awareness and infrastructure.
- Gene therapy and precision medicine remain rarely accessible outside major cities.
A similar Right-to-Try law in India could:
- Enable families to access experimental treatments before formal approval.
- Reduce the burden on clinical trial participants, who often face long wait times and ethical dilemmas.
- Encourage biotech innovation by providing a clear pathway for early-stage therapies.
However, implementation would require:
- Collaboration between state governments, pharmaceutical companies, and NGOs.
- Strengthening of healthcare infrastructure in rural areas.
- Clear ethical guidelines to prevent misuse of experimental treatments.
Brody’s Story: A Global Lesson in Healthcare Access
Kris DeVault’s journey with Brody is a microcosm of the global rare disease crisis. When he first sought help, Montana’s healthcare system was ill-equipped to diagnose and treat CTD. It took years before Brody was connected to a specialized neurology center, and even then, no cure existed.
Yet, DeVault’s persistence led to a breakthrough: through Montana’s Right-to-Try Law, his son was able to participate in a clinical trial for a gene therapy in development. While the treatment is not yet FDA-approved, it represents a glimmer of hope for families worldwide.
Brody’s Impact on Global Healthcare Policy
DeVault’s story has influenced legislative discussions in the U.S., including:
- The Rare Disease Act (2017), which aims to accelerate FDA approvals for rare diseases.
- Proposals for a "Right-to-Try" model in other states, including New York and California.
Yet, the real challenge lies in scaling this model globally. Northeast India, with its unique healthcare challenges, could benefit from a hybrid approach:
- Decentralized clinical trials to reduce costs and improve access.
- Public-private partnerships to fund experimental treatments.
- Educational campaigns to raise awareness about rare diseases.
The Broader Implications: A New Era of Medical Innovation?
Montana’s Right-to-Try Law is not just a local success story—it is a potential global model for accessible healthcare innovation. Its implications extend beyond rare diseases, touching on:
- The ethics of medical access in an unequal world.
- The role of governments and corporations in ensuring equitable healthcare.
- The future of precision medicine in low-resource settings.
Regional Impact: Northeast India’s Path Forward
For Northeast India, the Right-to-Try concept could be a game-changer in:
- Rare Disease Research: Encouraging local clinical trials to reduce reliance on foreign institutions.
- Healthcare Equity: Ensuring that tribal and rural populations have access to cutting-edge treatments.
- Biotech Growth: Attracting investment in gene therapy and precision medicine.
However, success will depend on:
- Policy reforms to streamline regulatory approvals.
- Increased funding for rare disease research.
- Strong public-private partnerships to bridge the healthcare divide.
A Call for Global Collaboration
The story of Brody and Montana’s Right-to-Try Law reminds us that medical innovation is not just about science—it’s about human lives. In Northeast India, where neurological disorders are a silent epidemic, the time has come to rethink healthcare access.
By learning from Montana’s model, India can create a system where no child has to suffer in silence because of a lack of treatment. The question is no longer if such a system is possible—but how soon can we build it?
Conclusion: The Future of Accessible Healthcare
Montana’s Right-to-Try Law is more than a legislative achievement—it is a revolution in how we think about medical access. For families like Brody’s, it means hope in the face of despair. For Northeast India, it offers a blueprint for a healthcare system that prioritizes life over bureaucracy.
The challenge ahead is scaling this model globally, ensuring that no child, no matter where they live, has to wait for a cure. As we move forward, we must ask:
- How can we make experimental treatments accessible to all?
- What role should governments play in ensuring equitable healthcare?
- Can we turn the tide on rare diseases before it’s too late?
The answer lies in bold innovation, ethical courage, and a commitment to human dignity. Brody’s story is not just about Montana—it is about the world’s most vulnerable children, waiting for a future where medicine is not a privilege, but a right.
Final Thought: In a world where science races ahead but access lags behind, Montana’s Right-to-Try Law is a beacon—proving that sometimes, the most radical idea is the one that saves lives.